Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 708-713

  Sasaki, Takashi ^a   Isayama, Hiroyuki ^a   Nakai, Yousuke ^a   Mizuno, Suguru ^a   Yamamoto, Keisuke ^a   Yagioka, Hiroshi ^b   Yashima, Yoko ^c   Kawakubo, Kazumichi ^a   Kogure, Hirofumi ^a   Togawa, Osamu ^a   Matsubara, Saburo ^d   Ito, Yukiko ^c   Sasahira, Naoki ^a   Hirano, Kenji ^a   Tsujino, Takeshi ^c   Toda, Nobuo ^e   Tada, Minoru ^a   Omata, Masao ^f   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JR Tokyo General Hospital   (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^d The Mutualaid Association of Public School Teachers)   (Japan)

^e MITSUI MEMORIAL HOSPITAL   (Japan)

^f Yamanashi Prefectural Hospital Organization   (Japan)

Author keywords

Biliary tract cancer; Gemcitabine; S 1; Secondline

Indexed keywords

CISPLATIN; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; OTERACIL; S 1 (COMBINATION); TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIARY TRACT CANCER; BILIARY TRACT SURGERY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKOPENIA; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RETREATMENT; SIDE EFFECT; SKIN PIGMENTATION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; BILIARY TRACT TUMOR; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG RESISTANCE; JAPAN; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; RADIOGRAPHY; TIME; TREATMENT FAILURE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OXONIC ACID; TEGAFUR; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT FAILURE;

EID: 84862253117     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9553-9     Document Type: Article

References (20)

1. National Cancer Center. Cancer statistics in Japan 2009. http://www.fpcr.or.jp/publication/statistics.html. Accessed 1 August, 2010.
2. Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96 (6):896-902
3. Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E et al (2005) Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol 23(10):2332-2338
4. Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O et al (2008) Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 99(6):862-867
5. Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O et al (2010) Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol 65(6):1101-1107
6. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl JMed 362(14):1273-1281
7. Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A et al (2010) Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer 103(4):469-474
8. Lee MA, Woo IS, Kang JH, Hong YS, Lee KS (2004) Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases. Jpn J Clin Oncol 34(9):547-550
9. Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C et al (2007) Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology 72(1-2):105-110
10. Oh SY, Jeong CY, Hong SC, Kim TH, Ha CY, Kim HJ, et al. Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness. Invest New Drugs 2010 (in press).
11. Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H et al (2010) Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer. Invest New Drugs (in press).
12. Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C (2004) Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer 91(10):1769-1774
13. Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T et al (2008) S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol 62(5):849-855
14. Park I, Lee JL, Ryu MH, Kim TW, Chang HM, Lee SS et al (2009) Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patients. Oncology 76(2):126-132
15. Sasaki T, Isayama H, Yashima Y, Yagioka H, Kogure H, Arizumi T et al (2009) S-1 monotherapy in patients with advanced biliary tract cancer. Oncology 77(1):71-74
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3):205-216
17. Fleming TR (1982) One-sample multiple testing procedure for phase II clinical trials. Biometrics 38(1):143-151
18. Suzuki E, Ikeda M, Okusaka T, Nakamori S, Ohkawa S, Nagakawa T et al (2010) A multicenter phase II of S-1 in gemcitabine-refractory biliary tract cancer. Proc Am Soc Clin Oncol 28:15s, abstract no: 4145
19. Yonemoto N, Furuse J, Okusaka T, Yamao Funakoshi A, Ohkawa S et al (2007) A multi-centerretrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol 37(11):843-851
20. Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y et al (2010) Prognostic factors in patientswith advanced biliary tract cancer receiving chemotherapy. Cancer Chemother Pharmacol (in press)